POST Online Media Lite Edition



 

Pfizer hikes U.S. prices for more than 100 drugs

Staff writer |
Pfizer on January 1 raised U.S. prices for more than 100 of its drugs, some by as much as 20 percent, according to statistics compiled by Wolters Kluwer.

Article continues below






Pfizer confirmed a 9.4 percent increase for heavily advertised pain drug Lyrica, which generated $2.3 billion in 2014 U.S. sales; a 12.9 percent increase for erectile dysfunction drug Viagra, which had 2014 U.S. sales of $1.1 billion; and a 5 percent increase for Ibrance, a novel breast cancer drug launched last year at a list price of $9,850 per month, or $118,200 per year.

Those price increases were compiled by a unit of Wolters Kluwer Health and published in a research note by UBS Securities. UBS said Pfizer increased prices by 20 percent for anticonvulsant Dilantin, hormone therapy Menest, angina drug Nitrostat, Tykosyn for irregular heartbeat, and antibiotic Tygacil.

The analyst report said U.S. prices were raised on a total of 105 Pfizer drugs. No price reductions were reported.


What to read next

Pfizer considers $100 billion bid for AstraZeneca
Pfizer has green light from EU for $15 billion Hospira acquisition
Pfizer to sell infusion business to ICU Medical